Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
AC Immune SA has a consensus price target of $11.33 based on the ratings of 3 analysts. The high is $16 issued by HC Wainwright & Co. on September 18, 2024. The low is $8 issued by BTIG on May 31, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., BTIG, and HC Wainwright & Co. on September 18, 2024, May 31, 2024, and March 15, 2024, respectively. With an average price target of $13.33 between HC Wainwright & Co., BTIG, and HC Wainwright & Co., there's an implied 285.36% upside for AC Immune SA from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for AC Immune (NASDAQ:ACIU) was reported by HC Wainwright & Co. on September 18, 2024. The analyst firm set a price target for $16.00 expecting ACIU to rise to within 12 months (a possible 362.43% upside). 4 analyst firms have reported ratings in the last year.
The latest analyst rating for AC Immune (NASDAQ:ACIU) was provided by HC Wainwright & Co., and AC Immune reiterated their buy rating.
There is no last upgrade for AC Immune
There is no last downgrade for AC Immune.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of AC Immune, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for AC Immune was filed on September 18, 2024 so you should expect the next rating to be made available sometime around September 18, 2025.
While ratings are subjective and will change, the latest AC Immune (ACIU) rating was a reiterated with a price target of $16.00 to $16.00. The current price AC Immune (ACIU) is trading at is $3.46, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.